The Causal-Benefit Model to Prevent Cardiovascular Events.

Area of Science:

• Cardiovascular Medicine
• Preventive Cardiology
• Lipid Metabolism

Background:

• Current guidelines for preventive lipid-lowering therapy rely on a 10-year cardiovascular disease (CVD) risk model.
• This model limits eligibility, particularly for individuals under 65, despite a significant proportion of CVD events occurring in this age group.
• CVD often develops and progresses before age 65, even if events manifest later.

Purpose of the Study:

• To evaluate the efficacy of a causal-benefit model for selecting individuals for preventive lipid-lowering therapy.
• To compare the causal-benefit model with the existing 10-year risk model in terms of patient eligibility and event prevention.
• To assess the cost-effectiveness of the proposed causal-benefit model.

Main Methods:

• The study proposes a causal-benefit model that integrates individual CVD risk with the estimated benefit of lowering atherogenic apoB lipoprotein levels.
• This model identifies candidates for preventive therapy based on a dual assessment of risk and treatment benefit.
• Comparative analysis with the standard 10-year risk stratification was performed to determine differences in eligibility and outcomes.

Main Results:

• The causal-benefit model significantly increases the number of younger individuals eligible for preventive lipid-lowering therapy.
• Adoption of this model is projected to prevent a greater total number of CVD events.
• The enhanced prevention is achievable with a comparable number of individuals requiring treatment, indicating improved efficiency.

Conclusions:

• The causal-benefit model offers a more inclusive and effective approach to preventive lipid-lowering therapy compared to the current 10-year risk model.
• This model expands treatment eligibility to younger populations at risk and those who would benefit most from lowering apoB.
• Implementing the causal-benefit model is expected to be cost-effective and lead to a substantial reduction in cardiovascular disease burden.